Moleculin Biotech is trading 6.18% down at $0.53 in pre-market, with no company-specific announcement identified for September 23, 2026. - Recent coverage highlights an earlier Nasdaq minimum-bid-price compliance issue and upcoming Annamycin presentations; neither directly explains the decline. - The broader biotech sector is higher, so sector strength does not explain the move; the catalyst remains unclear.